Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has been awarded an SBRI grant from Innovate UK to assist in the development of an ultra-rapid POC multiplex STI test measuring the four most commonly occurring pathogens (Chlamydia trachomatis, Neisseria gonorrhoea, Trichomonas vaginalis and Mycoplasma genitalium) in less than 30 minutes.
Atlas Genetics will develop an ultra-rapid POC stratified medicine diagnostic for patients presenting to Sexual Health Clinics with urethritis, which will allow immediate and accurate selection of appropriate and effective antibiotic treatment. Atlas will be collaborating with the Applied Diagnostic Research and Evaluation Unit at St George’s, University of London and Aquarius Population Health. Key elements of this project include cost-effectiveness modelling of introducing this multi-pathogen test, as well as a study on its potential patient impact. The £150,000 grant will be shared between the three organisations.
John Clarkson, CEO of Atlas Genetics, said: “With our Chlamydia test now approved in Europe and our combined Chlamydia/Gonorrhoea test planned for clinical trials later this year, the next step for Atlas is to develop a multiplex test which covers the majority of pathogens for patients entering sexual health clinics. We are very excited to be working with St Georges and Aquarius Population Health on this important project.”
Dr Tariq Sadiq, Chief Investigator at St George’s, University of London, commented: “This is a very exciting development in the STI world. The diagnosis and treatment of sexually transmitted infections has become very challenging for doctors and this new test will allow for patients to have their precise infection identified to enable treatment with the correct antibiotics, immediately after they see a doctor.”
Dr Elisabeth Adams, Managing Director of Aquarius Population Health, added: “We are thrilled to collaborate on this project and develop evidence to demonstrate the likely costs, benefits and cost-effectiveness of an innovative STI test. Results have the potential to positively impact patient care, increase efficiency within the NHS, and improve antimicrobial stewardship.”